CARs on a highway with roadblocks.
作者信息
Galluzzi Lorenzo, Martin Peter
机构信息
Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, New York, NY, USA.
出版信息
Oncoimmunology. 2017 Oct 11;6(12):e1388486. doi: 10.1080/2162402X.2017.1388486. eCollection 2017.
Abstract
摘要
相似文献
1
CARs on a highway with roadblocks.
Oncoimmunology. 2017 Oct 11;6(12):e1388486. doi: 10.1080/2162402X.2017.1388486. eCollection 2017.
2
Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice.
J Oncol Pharm Pract. 2019 Jul;25(5):1217-1225. doi: 10.1177/1078155219836480. Epub 2019 Mar 19.
3
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Curr Hematol Malig Rep. 2019 Feb;14(1):47-55. doi: 10.1007/s11899-019-0498-6.
4
Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia.
J Adv Pract Oncol. 2018 Jul-Aug;9(5):537-544. Epub 2018 Jul 1.
5
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.
J Clin Oncol. 2018 Nov 10;36(32):3192-3202. doi: 10.1200/JCO.2018.79.0642. Epub 2018 Sep 13.
6
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6.
7
Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Expert Opin Biol Ther. 2018 Nov;18(11):1095-1106. doi: 10.1080/14712598.2018.1533951. Epub 2018 Oct 12.
8
Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
Drugs Today (Barc). 2017 Nov;53(11):597-608. doi: 10.1358/dot.2017.53.11.2725754.
9
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.
CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):285-295. doi: 10.1002/psp4.12388. Epub 2019 Mar 7.
10
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.
Front Oncol. 2019 Sep 19;9:917. doi: 10.3389/fonc.2019.00917. eCollection 2019.
引用本文的文献
1
A Proteomics Outlook on the Molecular Effectors of CAR-T Cell Therapy in Cancer Management.
J Proteome Res. 2025 Jun 6;24(6):2571-2583. doi: 10.1021/acs.jproteome.4c00930. Epub 2025 Mar 6.
2
CAR-T cell therapy: a game-changer in cancer treatment and beyond.
Clin Transl Oncol. 2024 Jun;26(6):1300-1318. doi: 10.1007/s12094-023-03368-2. Epub 2024 Jan 20.
3
Understanding cell culture dynamics: a tool for defining protocol parameters for improved processes and efficient manufacturing using human embryonic stem cells.
Bioengineered. 2021 Dec;12(1):979-996. doi: 10.1080/21655979.2021.1902696.
4
Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
MAbs. 2020 Jan-Dec;12(1):1834818. doi: 10.1080/19420862.2020.1834818.
5
Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.
Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.
6
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.
Oncoimmunology. 2018 Feb 15;7(6):e1433982. doi: 10.1080/2162402X.2018.1433982. eCollection 2018.
本文引用的文献
1
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19.
2
CAR T-cells: an exciting frontier in cancer therapy.
Lancet. 2017 Sep 9;390(10099):1006. doi: 10.1016/S0140-6736(17)32395-4.
3
Chimeric Antigen Receptor (CAR) T-Cell Therapy.
JAMA Oncol. 2017 Nov 1;3(11):1595. doi: 10.1001/jamaoncol.2017.2989.
4
The Principles of Engineering Immune Cells to Treat Cancer.
Cell. 2017 Feb 9;168(4):724-740. doi: 10.1016/j.cell.2017.01.016.
5
Fine-tuning the CAR spacer improves T-cell potency.
Oncoimmunology. 2016 Nov 8;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016.
6
Engineered T cells: the promise and challenges of cancer immunotherapy.
Nat Rev Cancer. 2016 Aug 23;16(9):566-81. doi: 10.1038/nrc.2016.97.
7
Toxicities of chimeric antigen receptor T cells: recognition and management.
Blood. 2016 Jun 30;127(26):3321-30. doi: 10.1182/blood-2016-04-703751. Epub 2016 May 20.
8
Trial Watch-Oncolytic viruses and cancer therapy.
Oncoimmunology. 2015 Dec 8;5(2):e1117740. doi: 10.1080/2162402X.2015.1117740. eCollection 2016 Feb.
9
Driving CAR T-cells forward.
Nat Rev Clin Oncol. 2016 Jun;13(6):370-83. doi: 10.1038/nrclinonc.2016.36. Epub 2016 Mar 22.
10
CAR-T cells are serial killers.
Oncoimmunology. 2015 Jun 1;4(12):e1053684. doi: 10.1080/2162402X.2015.1053684. eCollection 2015 Dec.
Zotero 插件